Generate Biomedicines, Inc. (GENB)

Generate Biomedicines Statistics

Total Valuation

GENB has a market cap or net worth of $1.66 billion. The enterprise value is $1.21 billion.

Market Cap	1.66B
Enterprise Value	1.21B

Important Dates

The last earnings date was Thursday, May 7, 2026, before market open.

Earnings Date	May 7, 2026
Ex-Dividend Date	n/a

Share Statistics

GENB has 127.45 million shares outstanding.

Current Share Class	127.45M
Shares Outstanding	127.45M
Shares Change (YoY)	n/a
Shares Change (QoQ)	+97.83%
Owned by Insiders (%)	4.08%
Owned by Institutions (%)	23.60%
Float	59.57M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	54.70
Forward PS	62.50
PB Ratio	3.24
P/TBV Ratio	3.22
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	39.82
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 9.17, with a Debt / Equity ratio of 0.13.

Current Ratio	9.17
Quick Ratio	8.85
Debt / Equity	0.13
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-264.23

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-44.24%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	$97,112
Profits Per Employee	-$850,772
Employee Count	312
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, GENB has paid $135,000 in taxes.

Income Tax	135,000
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	12.95
200-Day Moving Average	n/a
Relative Strength Index (RSI)	46.00
Average Volume (20 Days)	449,548

Short Selling Information

The latest short interest is 3.18 million, so 2.49% of the outstanding shares have been sold short.

Short Interest	3.18M
Short Previous Month	2.08M
Short % of Shares Out	2.49%
Short % of Float	5.34%
Short Ratio (days to cover)	9.38

Income Statement

In the last 12 months, GENB had revenue of $30.30 million and -$265.44 million in losses. Loss per share was -$4.57.

Revenue	30.30M
Gross Profit	-194.40M
Operating Income	-251.02M
Pretax Income	-240.23M
Net Income	-265.44M
EBITDA	-237.99M
EBIT	-251.02M
Loss Per Share	-$4.57

Balance Sheet

The company has $516.64 million in cash and $65.57 million in debt, with a net cash position of $451.07 million or $3.54 per share.

Cash & Cash Equivalents	516.64M
Total Debt	65.57M
Net Cash	451.07M
Net Cash Per Share	$3.54
Equity (Book Value)	514.80M
Book Value Per Share	4.02
Working Capital	477.00M

Cash Flow

In the last 12 months, operating cash flow was -$227.83 million and capital expenditures -$6.54 million, giving a free cash flow of -$234.38 million.

Operating Cash Flow	-227.83M
Capital Expenditures	-6.54M
Depreciation & Amortization	13.04M
Net Borrowing	-6.63M
Free Cash Flow	-234.38M
FCF Per Share	-$1.84

Margins

Gross Margin	n/a
Operating Margin	-828.49%
Pretax Margin	-792.86%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

GENB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-16.01%
FCF Yield	-14.14%

Analyst Forecast

The average price target for GENB is $25.40, which is 95.31% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$25.40
Price Target Difference	95.31%
Analyst Consensus	Strong Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	58.42%
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1